Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

被引：21

作者：

Passaro, Antonio ^{[1
]}

Lazzari, Chiara ^{[1
,2
]}

Karachaliou, Niki ^{[3
]}

Spitaleri, Gianluca ^{[1
]}

Pochesci, Alessia ^{[1
]}

Catania, Chiara ^{[1
]}

Rosell, Rafael ^{[4
]}

de Marinis, Filippo ^{[1
]}

机构：

[1] European Inst Oncol, Div Thorac Oncol, Via G Ripamonti 435, I-20141 Milan, Italy

[2] Ist Sci San Raffaele, Div Expt Med, Dept Med Oncol, Milan, Italy

[3] Quiron Dexeus Univ Hosp, Oncol Inst Dr Rosell, Barcelona, Spain

[4] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

来源：

ONCOTARGETS AND THERAPY | 2016年 / 9卷

关键词：

ALK; NSCLC; crizotinib; ceritinib; alectinib; brigatinib; lorlatinib; brain metastases; MULTICENTER PHASE-II; EML4-ALK FUSION TRANSCRIPTS; MULTIPLEXED GENE-EXPRESSION; CIRCULATING TUMOR-CELLS; INHIBITOR ALECTINIB; ANAPLASTIC LYMPHOMA; ANTITUMOR-ACTIVITY; CRIZOTINIB RESISTANCE; ACQUIRED-RESISTANCE; BRAIN METASTASES;

D O I：

10.2147/OTT.S98347

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second-or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naive ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.

引用

页码：6361 / 6376

页数：16

共 109 条

[1]

[Anonymous], J CLIN ONCOL S

[2] RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics [J].

Best, Myron G. ;

Sol, Nik ;

Kooi, Irsan ;

Tannous, Jihane ;

Westerman, Bart A. ;

Rustenburg, Francois ;

Schellen, Pepijn ;

Verschueren, Heleen ;

Post, Edward ;

Koster, Jan ;

Ylstra, Bauke ;

Ameziane, Najim ;

Dorsman, Josephine ;

Smit, Egbert F. ;

Verheul, Henk M. ;

Noske, David P. ;

Reijneveld, Jaap C. ;

Nilsson, R. Jonas A. ;

Tannous, Bakhos A. ;

Wesseling, Pieter ;

Wurdinger, Thomas .

CANCER CELL, 2015, 28 (05) :666-676

[3] A framework for understanding and targeting residual disease in oncogene-driven solid cancers [J].

Bivona, Trever G. ;

Doebele, Robert C. .

NATURE MEDICINE, 2016, 22 (05) :472-478

[4] ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma [J].

Bresler, Scott C. ;

Weiser, Daniel A. ;

Huwe, Peter J. ;

Park, Jin H. ;

Krytska, Kateryna ;

Ryles, Hannah ;

Laudenslager, Marci ;

Rappaport, Eric F. ;

Wood, Andrew C. ;

McGrady, Patrick W. ;

Hogarty, Michael D. ;

London, Wendy B. ;

Radhakrishnan, Ravi ;

Lemmon, Mark A. ;

Mosse, Yael P. .

CANCER CELL, 2014, 26 (05) :682-694

[5] Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma [J].

Cai, Weijing ;

Lin, Dongmei ;

Wu, Chunyan ;

Li, Xuefei ;

Zhao, Chao ;

Zheng, Limou ;

Chuai, Shannon ;

Fei, Ke ;

Zhou, Caicun ;

Hirsch, Fred R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) :3701-+

[6] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[7] Treating ALK-positive lung cancer-early successes and future challenges [J].

Camidge, D. Ross ;

Doebele, Robert C. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (05) :268-277

[8] Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus [J].

Cappuzzo, Federico ;

Moro-Sibilot, Denis ;

Gautschi, Oliver ;

Boleti, Ekaterini ;

Felip, Enriqueta ;

Groen, Harry J. M. ;

Germonpre, Paul ;

Meldgaard, Peter ;

Arriola, Edurne ;

Steele, Nicola ;

Fox, Jesme ;

Schnell, Patrick ;

Engelsberg, Arne ;

Wolf, Juergen .

LUNG CANCER, 2015, 87 (02) :89-95

[9] Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene [J].

Chen, Zhao ;

Sasaki, Takaaki ;

Tan, Xiaohong ;

Carretero, Julian ;

Shimamura, Takeshi ;

Li, Danan ;

Xu, Chunxiao ;

Wang, Yuchuan ;

Adelmant, Guillaume O. ;

Capelletti, Marzia ;

Lee, Hyun Joo ;

Rodig, Scott J. ;

Borgman, Christa ;

Park, Seung-il ;

Kim, Hyeong Ryul ;

Padera, Robert ;

Marto, Jarrod A. ;

Gray, Nathanael S. ;

Kung, Andrew L. ;

Shapiro, Geoffrey I. ;

Jaenne, Pasi A. ;

Wong, Kwok-Kin .

CANCER RESEARCH, 2010, 70 (23) :9827-9836

[10] Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer [J].

Choi, Young Lim ;

Takeuchi, Kengo ;

Soda, Manabu ;

Inamura, Kentaro ;

Togashi, Yuki ;

Hatano, Satoko ;

Enomoto, Munehiro ;

Hamada, Toru ;

Haruta, Hidenori ;

Watanabe, Hideki ;

Kurashina, Kentaro ;

Hatanaka, Hisashi ;

Ueno, Toshihide ;

Takada, Shuji ;

Yamashita, Yoshihiro ;

Sugiyama, Yukihiko ;

Ishikawa, Yuichi ;

Mano, Hiroyuki .

CANCER RESEARCH, 2008, 68 (13) :4971-4976

← 1 2 3 4 5 6 7 8 9 10 →